REG - Oxford BioDynamics - OBD partners with The London Clinic for PSE & CiRT

Oxford BiodynamicsAnnouncement

21/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240521:nRSU1841Pa&default-theme=true

RNS Number : 1841P  Oxford BioDynamics PLC  21 May 2024

 

Oxford BioDynamics
("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

Oxford BioDynamics partners with The London Clinic to offer

EpiSwitch® PSE and CiRT oncology tests

 

·  The London Clinic is one of the UK's largest private hospitals, situated
in London's Harley Street medical district

·   OBD's EpiSwitch PSE and CiRT tests will be added to The London Clinic's
oncology toolbox

·   Agreement provides physician and patient access to EpiSwitch diagnostic
tests at the newly opened state-of-the-art Rapid Diagnostics Centre
(https://www.thelondonclinic.co.uk/media-hub/the-london-clinic-opens-new-rapid-diagnostics-centre)

 

Oxford, UK - 21 May 2024 - Oxford BioDynamics Plc (AIM: OBD, the "Company"), a
biotechnology company developing precision medicine tests based on the
EpiSwitch® 3D genomics platform, and The London Clinic, one of the UK's
leading private hospitals, have signed an agreement to give The London Clinic
patients access to OBD's EpiSwitch PSE (EpiSwitch Prostate Screening) and
EpiSwitch CiRT (Checkpoint inhibitor Response Test) blood tests.

The London Clinic is the UK's largest independent charitable hospital,
situated in London's renowned medical district at Harley Street. The
organisation works with all major UK and many international private medical
insurers, with its doctors treating around 155 different conditions. The
integration of OBD's EpiSwitch PSE test into The London Clinic's suite of
oncology diagnostics aligns with the recent opening of its state-of-the-art
six-floor Rapid Diagnostics Centre
(https://www.thelondonclinic.co.uk/media-hub/the-london-clinic-opens-new-rapid-diagnostics-centre)
opposite its main hospital.

"We know that cancer treatment outcomes are hugely influenced by accurate and
early diagnosis, and it's crucial we give our doctors the tools they need to
predict if patients will respond to potentially life-saving medicines. The
qualities of OBD's accurate PSE and CiRT tests align with our commitment to
providing cutting-edge innovation and excellence in personalised patient care.
Both of these tests can play an important part in helping our doctors and
patients save valuable time in making an informed decision about their health,
and getting on track to receiving the required care," said Dr Rowan Miller,
Clinical Director for Oncology at The London Clinic.

OBD's EpiSwitch PSE test is a blood test that boosts the predictive accuracy
of a standard PSA test from 55% to 94% when testing for the presence or
absence of prostate cancer, which was launched in the UK and US in September
2023 (see www.94percent.com (http://www.94percent.com) ). The PSE test is the
culmination of nearly ten years of collaborative work between OBD, Imperial
College London, the University of East Anglia, Imperial College NHS Trust, and
leading UK prostate cancer experts, as part of the PROSTAGRAM screening pilot.
As well as a high 94% accuracy, PSE offers high specificity, 97% (standard PSA
alone: 53%), and high sensitivity, 86% (PSA: 64%), as well as high positive,
93% (PSA: 25%(1)), and high negative, 95% (PSA: 86%(1)) predictive values to
assess the risk of prostate cancer in men, published in the peer-reviewed
publication, Cancers(2).

The EpiSwitch CiRT test will be available to The London Clinic doctors
considering treating their cancer patients with a widely used class of cancer
therapies: Immune Checkpoint Inhibitors (ICIs)(3). CiRT is a routine blood
test that accurately identifies patients who will respond to ICI therapy with
a binary result (responder vs. non-responder) to support first-line treatment
planning, and make more informed treatment decisions when no benefit or
disease progression is observed, or adverse events occur. The test can also
identify ICI candidates in patients where other options have been exhausted or
other tests are negative for use (see www.myCiRT.com (https://www.mycirt.com/)
).

Dr Jon Burrows, Chief Executive Officer of Oxford BioDynamics, said: "There is
a clear need for more accurate, minimally-invasive blood tests for detecting
prostate cancer and predicting response to immunotherapy. Through this new
partnership with The London Clinic we are delivering potentially life-changing
blood tests, which can safeguard the wellbeing of at-risk patients whilst
reducing the cost of care. This agreement follows our earlier joint
announcement with Bupa UK to provide coverage for the EpiSwitch CiRT test.
Joining forces with a world-class hospital like The London Clinic will enhance
access to the EpiSwitch PSE and CiRT tests in a centre of excellence in the
heart of London."

References

1.        NHS Health A to Z. Prostate cancer: PSA testing (2021).
https://www.nhs.uk/conditions/prostate-cancer/psa-testing
(https://www.nhs.uk/conditions/prostate-cancer/psa-testing)

2.        Pchejetski D, Hunter E, Dezfouli M, et al. (2023).
Circulating Chromosome Conformation Signatures Significantly Enhance PSA
Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection.
Cancers. 2023; 15(3):821. https://doi.org/10.3390/cancers15030821
(https://doi.org/10.3390/cancers15030821)

3.        Hunter, E., et al. (2023). Development and validation of
blood‐based predictive biomarkers for response to PD‐1/PD-L1 checkpoint
inhibitors: evidence of a universal systemic core of 3D immunogenetic
profiling across multiple oncological indications, Cancers 15(10), 2696.
https://doi.org/10.3390/cancers15102696
(https://doi.org/10.3390/cancers15102696)

- Ends -

 

 For further details please contact:
 Oxford BioDynamics Plc                                             +44 (0)1865 518910

 Jon Burrows, CEO

 Paul Stockdale, CFO

 Shore Capital                                                      +44 (0)20 7408 4090

(Nominated Adviser and Broker to OBD)

 Advisory: Stephane Auton / Lucy Bowden

 Broking: Fiona Conroy

 WG Partners                                                        +44 (0)20 3705 9330

 (Joint Broker to OBD)

 David Wilson / Claes Spång / Sateesh Nadarajah / Erland Sternby

 Instinctif Partners                                                Tel: +44 (0)20 7457 2020 OxfordBioDynamics@instinctif.com
 (Media / Analyst enquiries for OBD)

Melanie Toyne-Sewell / Katie Duffell / Jack Kincade

 The London Clinic (Press Office)                                   pressoffice@thelondonclinic.co.uk (mailto:pressoffice@thelondonclinic.co.uk)

Tel: +44 (0)7841 049 746
 Alice McIlhone, Content and Communications Manager

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing
personalized healthcare by developing and commercializing precision medicine
tests for life-changing diseases.

Its flagship products are the EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjphN2EwOmU5ZDc2NmYxZjYxNTk4OGE3YzY3NzkzYWRmODlmMmZmMzBmZmU2ZDZlZmNhMWI0ZmRlYjE3Nzc5N2Q4NmUzZTc6cDpU)
(Checkpoint Inhibitor Response Test) and EpiSwitch® PSE
(https://url.avanan.click/v2/___http:/www.94percent.com/___.YXAxZTpzaG9yZWNhcDphOm86NDM3OWRhZTU0OTFmMzEyYzg3YTA3NTlmNzczMzUyYTY6NjplNjRjOjkyNjc0OWI0ZDVjYmU1OWRkNmM4YTg4NzgyZDc4MDM1OWM0YzA0MzcxYjZjYzYzYzY0YmZhYWUzYTAzYzJjYjM6cDpU)
(EpiSwitch Prostate Screening test) blood tests. CiRT is a predictive immune
response profile for immuno-oncology (IO) checkpoint inhibitor treatments,
launched in February 2022. PSE is a blood test that boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or absence of
prostate cancer, which was launched in the US and UK in September 2023.

In March 2021, the Company launched its first commercial prognostic test,
EpiSwitch® CST
(https://url.avanan.click/v2/___https:/covidseveritytest.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjpmZWY1OmMzOGIyYTk2Yjk1OTgyMDNlMGFkNmQwZGU3ZmNmYzQwMzZmMGIwZDQ5NzA0OTAzNDc0NzY2ZDQyZGZiYjk5YWU6cDpU)
(Covid Severity Test) and the first commercially available microarray kit for
high-resolution 3D genome profiling and biomarker discovery, EpiSwitch®
Explorer Array Kit
(https://url.avanan.click/v2/___https:/store.oxfordbiodynamics.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjpiMWU2OjMzMTc0NWQ5ZWZhODg0MmY1N2EzZjY2YWRkZDI5YjBkOTRhM2M0ZTZkOGJkNWM2Y2I5MDE4MmQ4M2Y4ZjViMDY6cDpU)
, which is available for purchase by the life science research community.

The Company's product portfolio is based on a proprietary 3D genomic biomarker
platform, EpiSwitch®, which can build molecular diagnostic classifiers for
the prediction of response to therapy, patient prognosis, disease diagnosis
and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big
pharma and leading institutions including Pfizer, EMD Serono, Genentech,
Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi
Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker
arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an
expertly curated 3D genome knowledgebase comprising hundreds of millions of
data points from over 15,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock
Exchange. It also has a commercial office in Gaithersburg and a clinical
laboratory in Frederick, MD, USA, and a reference laboratory in Penang,
Malaysia.

For more information, please visit the Company's website,
www.oxfordbiodynamics.com
(https://url.avanan.click/v2/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo3ZjFmOjUxZjRiNmRmMzBiMGI3ZjA2NDJjNjFkZTc2MTM5MThjYjUxZGNiN2ZhNmRhNWRkMjY0MTAwNWY4ODA3ZjE4ZjU6cDpU)
, or follow OBD on Twitter
(https://url.avanan.click/v2/___https:/twitter.com/OxBioDynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjplM2FmOjIwMTI1ZWNlOWJkYjRjZDQ1YjA4YWI2NDc0NWY1OWYzNzg1NTEzYjM0NjIwYTZmNTljNjk0YTQ1YzBkMjg0OTM6cDpU)
(@OxBioDynamics) and LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo2YjgzOjcwMGI3YTM5ODdkMDVmNjA5ZDgxN2FmYWVjYTJkMjIzM2E3NTgzYzM0ZGIzMGIyZDIyYWZlZTVjN2QyZmY4ZGQ6cDpU)
.

 

About The London Clinic

The London Clinic is a leading private charitable hospital, situated in
Harley Street, the heart of London's medical district. Opened in February 1932
by the Duke and Duchess of York (later becoming King George VI), The London
Clinic has been at the forefront of healthcare for over 90 years.

Her Majesty The Queen (formerly HRH The Duchess of Cornwall) is The London
Clinic's Patron.

The London Clinic's services are provided across seven buildings housing
eleven theatres, 190 beds, consulting rooms, and a wide range of diagnostic
services, including the latest 3T MRI scanner. The Duchess of Devonshire Wing,
The London Clinic's custom-built cancer centre, spans eight floors, offering
access to state-of-the-art radiotherapy and chemotherapy suites, along with
Europe's largest private stem cell collection and storage facility. We were
the first independent hospital in the UK to gain the Joint Accreditation
Committee ISCT Europe and EBMT (JACIE) accreditation in recognition of our
quality standards in stem cell work. We also have a Rapid Diagnostics Centre
(opened February 2024) which focuses on urology
(https://www.thelondonclinic.co.uk/services/diagnostics/rapid-urology) ,
gynaecology
(https://www.thelondonclinic.co.uk/services/diagnostics/rapid-gynaecology) ,
breast
(https://www.thelondonclinic.co.uk/services/diagnostics/one-stop-breast-clinic)
and dermatology
(https://www.thelondonclinic.co.uk/services/diagnostics/dermatology-clinic) ,
as well as supports a focus on early diagnosis particularly in cancer.

As a full-service hospital, The London Clinic offers the most comprehensive
range of services of any UK private hospital, including a 13-bed, Level 3
Intensive Care Unit and in-house pathology laboratory. We employ over 1,300
expert nurses, allied healthcare professionals, doctors, and support roles.
Our 900 world-class consultants specialise in cancer care, digestive diseases,
orthopaedics (including hips, knees, shoulders, and fingers with on-site
physiotherapy rehabilitation), neurology, cosmetic surgery, liver services,
gastroenterology, urology, endoscopy, diabetes, haematology, and
endocrinology.

As a charity, The London Clinic reinvests all profits to further our mission
of advancing healthcare within our hospital and for the benefit of the
healthcare community. We were the first private hospital in the UK to
introduce robotic surgery for prostate cancer and SpyGlass technology for
endoscopy. We continue to invest significantly in the education of our people,
supporting nurses to complete their degrees and fellows to become
consultants. 

 

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By
mapping this architecture and identifying abnormal configurations, EpiSwitch®
can be used to diagnose patients or determine how individuals might respond to
a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics'
award-winning, proprietary platform that enables screening, evaluation,
validation and monitoring of 3D genomic biomarkers. The technology is fully
developed, based on testing of over 15,000 samples in 30 disease areas, and
reduced to practice.

In addition to stratifying patients with respect to anticipated clinical
outcomes, EpiSwitch® data offer insights into systems biology and the
physiological manifestation of disease that are beyond the scope of other
molecular modalities. The technology has performed well in academic medical
research settings and has been validated through its integration in biomarker
discovery and clinical development with big pharma.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPURCAUPCGRU